TRAUMEEL® PRODUCT MONOGRAPH6

Tolerability of Traumeel® has been demonstrated to be significantly greater than with conventional treatments.

Safety studies have indicated that Traumeel® is unlikely to interfere with antimicrobial first defences, the normal homeostatic process, kidney function or liver function.

Post-marketing surveillance has demonstrated very good tolerability for Traumeel® formulations with very few adverse effects.

Traumeel® is suitable for patients requiring first-line treatment for musculoskeletal injuries and inflammation. It may be particularly suitable for patients who are unable to tolerate conventional anti-inflammatory medication, or for those in whom such treatment is contraindicated.

Investigation of the efficacy and place in therapy of Traumeel® is ongoing, with further randomized controlled trials underway.

Heel is committed to research; an Atlas of Inflammation Resolution (AIR) was jointly created by Heel, Rostock University (Germany) and Harvard Medical School. Researchers are providing the most detailed understanding of acute inflammation and inflammation resolution to date.

Heel supports real-world clinical research; healthcare professionals are encouraged to share their clinical experiences by submitting clincal case reports. Further information is available on www.heel.com